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Abstract: In this study, we evaluated the impact of the successive bioaugmentation of the activated
sludge (AS) with the defined bacterial consortium on the activity and functional capacity of the
AS microorganisms. In parallel, the removal of low concentrations of the selected non-steroidal
anti-inflammatory drugs (ibuprofen, naproxen, diclofenac) and analgesic paracetamol was studied.
We found that the addition of the bacterial consortium consisting of three pharmaceuticals-degrading
strains Bacillus thuringiensis B1 (2015b), Stenotrophomonas maltophilia KB2, and Pseudomonas moorei
KB4 into the AS did not cause any significant changes in the biomass abundance and metabolic
activity of the AS microorganisms. Although, the successive bioaugmentation of the AS caused a
slight increase in the metabolic diversity, the intensity of carbohydrates usage, and metabolic richness.
Microorganisms in the bioaugmented and non-bioaugmented AS were able to degrade the mixture of
the analyzed drugs with similar efficiency, however, diclofenac was removed more effectively in the
bioaugmented AS. Several metabolites were identified and efficiently utilized, with the exception of
4-OH diclofenac. Two new diclofenac-degrading strains assigned as Serratia proteamaculans AS4 and
Rahnella bruchi AS7 were isolated from the diclofenac-treated AS.
Keywords: activated sludge; bacterial consortium; bioaugmentation; biodegradation; functional
capacity; non-steroidal anti-inflammatory drugs (NSAIDs); paracetamol; phylogenetic resolution
1. Introduction
A wide range of contaminants of emerging concerns (CEC), including pharmaceuticals and
personal care products are continuously introduced into various environmental matrices. Organic
pollutants are usually characterized by highly diversified structure, low water solubility, poor
biodegradability, and environmental persistence [1,2]. Noteworthy, for most drugs, including the
non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol, there are no strict monitoring
recommendations or discharges guidelines. Pharmaceuticals used within this study, ibuprofen (IBU),
naproxen (NPX), diclofenac (DCF), and paracetamol (APAP) have been detected in several natural
matrices, e.g., surface water [3,4], wastewater [5], soil and sludge [6–8] at a concentration range
from ng L−1 to µg L−1. Drugs remain active even at low concentrations, therefore, their presence
may lead to successive deterioration of water quality and have an adverse impact on the ecosystem
and human health [9]. The main sources of pharmaceuticals in the environment include domestic
and industrial wastewater from pharmaceuticals production, hospital effluents, landfill leachate,
Water 2020, 12, 1133; doi:10.3390/w12041133 www.mdpi.com/journal/water
Water 2020, 12, 1133 2 of 22
artificial recharge using reclaimed water, and infiltration of contaminated water from agricultural land.
To date, the conventional methods i.e., chlorination as well as the advanced treatment techniques e.g.,
the membrane bioreactors, nanofiltration, reverse osmosis, and carbon nanocomposites with magnetic
properties are not fully adapted for pharmaceuticals removal [2,9,10]. Moreover, some authors pointed
out that the biological treatment is a bottleneck for micro-pollutant removal [11].
The efficiency of analgesics biodegradation by conventional activated sludge (AS) and membrane
bioreactors was summarized by Tiwari et al. [9], who found almost 90%–100% removal efficiency of IBU
but only 55%–85% and 5%–45% removal efficiencies of NPX and DCF, respectively. The effectiveness
of the AS treatment can be further improved by bioaugmentation, however, the successful treatment
depends primarily on the behavior of the strains introduced to the environment, which are characterized
by the potential to alter the interplay within the native communities resulting in strong shifts in their
structure, with neutral, beneficial, or detrimental impacts. The behavior of the exogenous strains
introduced into the AS depends on their ability to survive and grow within the new habitat, compete
with autochthonous microorganisms for the acquisition of nutrients, and resilience to the changing
environmental conditions such as pH, temperature, and water availability [12]. The successive
bioaugmentation, which partly mitigates those problems, is based on the repetitive introduction
of highly competent and carefully selected bacteria, whose growth rate exceeds washout and
predation [13–16].
Some authors pointed out that microorganisms of one species may be replaced by others with
the same metabolic properties [17]. Indeed, most basic functions i.e., respiration, nutrient uptake, or
denitrification are rather constant and unrelated to microbial diversity. Contrary, processes carried
out by more specialized strains i.e., xenobiotics removal or detoxification, are vulnerable to microbial
diversity decrease. Environments subjected to the continuous influence of xenobiotics constitute a
valuable source of new isolates with increased metabolic properties [17]. Up to now, the number
of microorganisms capable of degrading the NSAIDs is limited, thus, there is an urgent need to
isolate new bacterial strains, especially those capable of utilizing polycyclic drugs characterized
by poor biodegradability, i.e., DCF and NPX [10,18]. In recent years, many authors highlighted
that biodegradation of xenobiotics by pure bacterial cultures fails to reflect the adequate behavior of
environmental microorganisms during xenobiotics degradation, mainly due to the synergistic metabolic
activities exhibited by microorganisms in communities. Thus, bioaugmentation based on microbial
consortia, where degradation processes are frequently dependent on the combined actions of various
species, is more often applied for the degradation of xenobiotic compounds with low susceptibility to
biodegradation. A combination of strains may be used to mimic naturally occurring communities,
enhance or imitate a degradation pathway, or degrade several target pollutants within the same
wastewater [19,20]. Zhang et al. [21] noticed that the microbial consortium used for APAP degradation
achieved higher removal rates and significantly better tolerance to APAP with a shorter adaptation time.
One of the crucial issues related to the degradation processes carried out by microorganisms concerns
the environmental concentrations, which are frequently much lower than doses used in lab-scale
degradation experiments. It must be taken into consideration that there are threshold concentrations of
xenobiotics necessary to induce catabolic enzymes, below which degradation is unperceived. Moreover,
the differences in the kinetics of the same biodegradation processes, but with different concentrations
of substrate and competition from other carbon sources at low levels are frequently observed [22,23].
Thus, the aim of this study included the following goals: (i) analyzing the impact of low
analgesics concentrations of 0.5 mg L−1 for NPX and DCF and 1 mg L−1 for IBU and APAP on the AS
microorganisms, (ii) establishing the influence of introduced microorganisms on the autochthonous
microflora, (iii) estimating the effectiveness of analgesics removal assisted by the consortium of
bacterial strains, (iv) studying the degradation processes and formation of secondary metabolites, and
(v) isolating new bacterial strains able to degrade DCF.
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2. Materials and Methods
2.1. Characteristics of the Activated Sludge
The AS was derived from the aerobic chamber of the wastewater treatment plant (WWTP)
Klimzowiec located in Chorzów, Poland. The AS characterization included determinations of pH,
sludge volume index (SVI), and mixed liquor suspended solids (MLSS) [24]. The microbial activity in
the AS was assayed via the quantification of the dehydrogenases (DHA) [25], nonspecific esterases
(NSEA) [26], and specific oxygen uptake rate (SOUR) [27]. The number of total heterotrophic bacteria
(THB) in the AS was determined after their extraction from the sludge [16] and enumerated according
to EN ISO 8199:2010 [28] (Table 1). The part of the AS was sterilized (three times at 3 day intervals,
121 ◦C, 40 min) for further analysis. Our preliminary studies indicated that autoclaving in such
conditions allowed to obtain sterile sludge, which was also confirmed by serial dilution plating.
Table 1. Characteristics of the activated sludge (AS) obtained from the Klimzowiec sewage plant.
Parameter Value
pH 7.713 ± 0.071
SVI, g cm−3 114.182 ± 1.665
MLSS, g L−1 3.667 ± 0.180
SOUR, mg O2 g−1 MLSS h−1 8.424 ± 0.621
DHA, mg TPF g−1 MLSS h−1 16.096 ± 0.952
NSEA, µg fluorescein g−1 MLSS h−1 23.012 ± 0.697
Number of the THB, log CFU g−1 MLSS−1 8.226 ± 0.992
2.2. Composition of Bacterial Consortium
The microbial consortium used for bioaugmentation of the AS included three environmental
bacterial strains: Bacillus thuringiensis B1 (2015b), Stenotrophomonas maltophilia KB2, and Pseudomonas
moorei KB4 derived from the Microbial Culture Collection in the Institute of Biology, Biotechnology
and Environmental Protection (Faculty of Natural Sciences, University of Silesia in Katowice, Poland).
All of the strains can degrade the selected NSAIDs: IBU, NPX, DCF, and analgesic drug, APAP (Table 2).
In preliminary studies, the most effective bacterial consortium with the appropriate proportions of
the particular bacterial strains was established. According to the obtained results, the initial optical
density of particular bacteria in the inoculum at a wavelength of 600 nm (OD600) was leveled-off to 0.1,
which corresponded with 2.7 × 105, 1.6 × 107, and 1.7 × 106 CFU mL−1 for B1 strain, KB2 strain, and
KB4 strain, respectively.
Table 2. Composition of the bacterial consortium for bioaugmentation of the AS.
Bacterial Strain Site of Isolation Degradation of Aromatics Reference
Bacillus thuringiensis
B1(2015b)
Contaminated soil
Jaworzno, Poland Ibuprofen, naproxen [29]
Stenotrophomonas
maltophilia KB2
Activated sludge
Miechowice, Poland
Naproxen, phenol,
mononithrophenols,
methylphenols
[30]
Pseudomonas moorei KB4 Activated sludgeChorzów, Poland
Paracetamol, diclofenac, phenol,
4-hydroxybenzoic acid [31]
2.3. Experimental Set-Up and Isolating Diclofenac-Degrading Strains
Before the experiment, the AS was diluted with the synthetic wastewater (SW) medium with
the following composition, g L−1: 0.285 C6H12O6; 0.69 CH3COONa; 0.145 NH4Cl; 0.06 KH2PO4;
0.04 K2HPO4; 0.069 NaCl; 0.026 CaCl2 and 0.145 KCl [16] to obtain the initial concentration of the
sludge biomass of 3.0 ± 0.5 g L−1, which reflected the average concentration of microorganisms
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desirable for the wastewater treatment process. The composition of the SW reflected the ratio of carbon,
nitrogen, and phosphorus in the effluents of the WWTP Klimzowiec.
Herein, six experimental conditions of the AS (assays) were designed (Figure 1A). The abiotic
control of the analgesics physicochemical decomposition was analyzed in the control SWc assay,
which was filled with the SW supplemented with the same doses of examined pharmaceuticals as
the other systems. The AS1 assay contained the AS supplemented with the NSAIDs, APAP, and
bacterial consortium. The assay AS2 was non-bioaugmented but fed with the NSAIDs and APAP.
The AS3 contained sterilized AS with NSAIDs, APAP, and bacterial consortium. The assay assigned
as AS4 served as the bioaugmented biotic control and contained the AS with bacterial consortium,
while the AS5 served as the non-bioaugmented biotic control. The experiment was conducted for
30 days at 23 ◦C with mixing. Every 7 days, the volume of the supernatant liquid was measured
and replaced with fresh SW which reflected the natural cycles occurring in the WWTP. The bacterial
consortium was introduced repeatedly every 7 days after the exchange of supernatant liquid to avoid
inoculated bacteria being washed out from the AS system. The AS was amended with the mixture of
IBU (1 mg L−1), APAP (1 mg L−1), NPX (0.5 mg L−1), and DCF (0.5 mg L−1). Every 7 days after the
medium exchange, the new doses of drugs were spiked to the appropriate initial concentrations. We
measured the concentration of the pharmaceuticals residue before the medium exchange to correctly
spike drugs to the assays and after the addition to verify that the proper concentration of the drugs
was introduced. The pharmaceutical removal was monitored in the 7-day time regime mimicking the
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Figure 1. Scheme of the experimental set-up. (A) Different non- or bioaugmented assays AS1–AS4 fed
with NSAIDs and APAP and control assay AS5, (B) scheme of the isolation of new DCF-degrading strains
from the DCF-treated AS by classical enrichment technique. NSAIDs—non-steroidal anti-inflammatory
drugs (IBU, NPX, and DCF); IBU—ibuprofen, NPX—naproxen, DCF—diclofenac, APAP—paracetamol.
Parallelly, new bacterial strains able to degrade DCF were isolated from the AS not subjected to
bioaugmentation using the classical enrichment technique [29]. Briefly, 10 mL of the AS was introduced
into 90 mL of 0.9% NaCl and supplemented with DCF at a concentration of 10 mg L−1 as a sole carbon
and energy source. The culture was incubated at 23 ◦C with shaking (130 rpm) for 5 weeks. If the
complete degradation of DCF was achieved, a higher dose of the drug was introduced. After the
adaptation of the AS microorganisms to 25 mg L−1 of DFC, 1 mL of sample was serially diluted from
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10−1 to 10−3 with the NaCl and spread onto the agar plates containing mineral salts medium (MSM)
with the following composition, g L−1: 3.78 Na2HPO4 × 12 H2O; 0.5 KH2PO4; 5.0 NH4Cl; 0.2 MgSO4 ×
7 H2O; 0.01 yeast extract [32] supplemented with 25 mg L−1 of DCF to obtain pure bacterial cultures.
The agar plates were incubated at 23 ◦C for 24 h, and single colonies were further proliferated on the
nutrient agar for the purity tests (Figure 1B).
2.4. Evaluating the Activated Sludge Quality and Impact of Bioaugmentation
To estimate the metabolic response and functional capacity of microorganisms from the repeatedly
bioaugmented AS as well as the condition of the non-bioaugmented AS, several different parameters
were measured.
2.4.1. Measuring the Dehydrogenases Activity
The activity of the AS microorganisms was assayed by quantifying the activity of dehydrogenases
based on the reduction of 2,3,5-triphenyltetrazolium chloride (TTC) (Avantor, Gliwice, Poland) into
red, insoluble 1,2,3-triphenyltetrazolium chloride (TPF) according to Miksch [33].
2.4.2. Analyzing the Chemical Oxygen Demand
In order to evaluate the concentration of organic substances in the wastewater, chemical oxygen
demand (COD) was measured every 7 days before medium exchange according to the APHA [24].
2.4.3. Enumerating the Total Heterotrophic Bacteria
The THB were extracted from the AS flocs by homogenization (10 s at 11,000 × g) and enumerated
on the lysogeny broth (LB, BTL, Poland) plates solidified with agar (BTL, Poland) and incubated for
24–72 h at 23 ◦C. THB was expressed as CFU mL−1.
2.4.4. Metabolic Activity of the AS Measuring by BIOLOG
The functional capacity of the AS microorganisms from different assays during the experimental
period was examined using the Biolog system with 96-well EcoPlatesTM and Biolog microstation
(BIOLOG Inc., Hayward, CA, USA). At the beginning of the experiment (t0) and after 30 days of
treatment (t30), 10 mL samples from the bioaugmented assays and respective controls were mixed with
90 mL of the sterile saline solution and shaken for 1 h at 130 rpm. Afterward, 120 µL of the prepared
suspensions were used to inoculate each well of the plates and incubated at 22 ± 1 ◦C in the dark for
5 days. The measurements of the absorbance in each well was performed at 590 nm at the beginning of
the experiment and every 12 h. The final results were obtained when the value curve plateau of the
average well color development (AWCD) or inflection point was reached (Microlog 4.01 software).
The non-linear model described by the Verhulst equation with the four-parameter logistic function was
used to calculate the specific rate of the increase in the microbial activity A(t) [16]:
A(t) =
Amax(
1 + b· exp(−k·t50)
) (1)
where Amax indicates the maximum microbial activity; t50 indicates the time at which the microbial
activity has reached half of its maximum, k relates to the steepness slope of A(t)—a function of time for
the utilization of each carbon source in the EcoPlateTM at t = t50; and b—the relative microbial activity
increase in an arbitrary constant.
The Avt50 parameter which indicated that the total microbial activity increased at the fastest rate
was calculated from the equation:
Avt50 =
∑n
i=1(ln b/k)
N
(2)
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The calculated parameter was used to compare the control and bioaugmented assays by estimating
the functional capacity indices, i.e., average well color development (AWCD), metabolic richness
index (S), Gini coefficient (G), Shannon–Weaver diversity index (H’ECO), and evenness (E). The carbon
sources utilized in the EcoPlatesTM were divided into seven groups: polymers, surfactants, phenolic
acids, carboxylic acids, amines, amino acids, and carbohydrates [34].
2.5. Measuring the Protein Concentration
In order to estimate indirectly the biomass abundance in the AS, the protein concentration was
estimated by the Bradford method [32] with bovine serum albumin as a control.
2.6. Multi-Locus Sequence Typing and Phylogenetic Analysis of the Newly Isolated Strains
Bacterial DNA was isolated from the pure cultures using the DNA commercial kit (GeneMatrix
Bacterial and Yeast Genomic DNA, Eurx, Gdan´sk, Poland). The initial molecular identification of
analyzed strains was performed by phylogenetic analysis based on the partial sequence of 16S rRNA
according to the protocol described by Marchlewicz et al. [29]. The nearest taxonomic group was
identified by the online tool BLASTN using DDBJ/EMBL/GenBank nucleotide sequence databases.
The 16S rRNA gene sequences have been stored in the GenBank database (NCBI) under the following
accession numbers: MT180428 and MT180429, for AS4 and AS7 strains, respectively. To provide
more detailed phylogenetic characteristics, sequencing of the partial sequences of two housekeeping
genes, rpoB and pyrG was performed [35]. The sequences of the examined genes were extracted
from fully sequenced representative genomes from the genera indicated in the 16S rRNA analysis
(Klebsiella, Serratia, and Enterobacter) in the PATRIC database [36]. The nucleotide sequences of
both genes were aligned separately in Geneious Prime® 2019.2.3 with global alignment on default
settings. The specific primers for both genes were designed from identical sites. For amplification of
the partial sequence of the rpoB gene primers: rpoB_F: 5’ ATGGTTTACTCCTATACCGAGAA 3’,
rpoB_R: 5’ GCATCATGCGGTAGATTTCTAC 3’ and for pyrG gene: pyrG_F: 5’ GTCGTATCC
TCTCTGGGTAAAG 3’, pyrG_R: 5’ TTAAGCTGAATCGTTTACAAATATAATC 3’ were used.
Amplification of both genes was carried out with a program consisting of initial denaturation
at 94 ◦C for 2 min, 30 cycles of denaturation at 94 ◦C for 15 s, annealing at 58 ◦C for 30 s, extension at
72 ◦C for 90 s, and a final elongation step at 72 ◦C for 7 min with Pfu DNA Polymerase (Eurx, Gdan´sk,
Poland). The partial nucleotide sequences of rpoB gene have been deposited in the GenBank database
of NCBI under the accession number MT181967 and MT181969, and pyrG gene under the accession
number MT181968 and MT181970 for AS4 and AS7 strains, respectively. Sequences for strains were
retrieved from the GenBank database and aligned separately for each gene in Geneious Prime and then
for each strain pyrG, rpoB, and 16S rRNA sequences were concatenated. The final alignment was used
to build a maximum likelihood (ML) phylogenetic tree in MEGA X version 10.1.5. The ML analysis was
performed with Tamura–Nei model with 1000 bootstrap phylogeny tests. The isolated strains will be
deposited in the publicly available German Collection of Microorganisms and Cell Cultures (DSMZ).
2.7. Measuring the Analgesics Concentrations
The concentration of tested drugs in the bioaugmented and non-bioaugmented assays and their
respective controls were determined using Merck Hitachi reversed-phase High-Performance Liquid
Chromatography (HPLC) with a column Ascentis Express® C18 (100× 4.6 mm), operated in an isocratic
mode, pre-column Opti-Solv® EXP, and UV/Vis diode array detector. The mobile phase for the
particular drugs detection was consisted as follows: acetonitrile: 1% acetic acid (50:50, v/v) for IBU and
NPX, methanol: 1% acetic acid (95:5, v/v) for APAP and acetonitrile: 1% acetic acid:methanol (50:30:20,
v/v/v) for DCF. The flow rate of the mobile phase was 1 mL min−1. The NSAIDs and APAP in the
supernatant were identified and quantified by comparing their HPLC retention times and UV-visible
spectra with respective parameters of external standards. The detection wavelength was 230, 240, 260,
and 276 nm for IBU, APAP, NPX, and DCF, respectively.
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2.8. Identifying the Intermediates Formed During Degradation
Every 7 days, the analyses of the secondary metabolites in the bioaugmented assays with the
NSAIDs and APAP were performed using liquid chromatography coupled with a mass detector
(UHPLC/MS/MS) Shimadzu LC/MS-8040 in reverse phase system, using a Luna Omega C18 1.6 µm
column, 100 × 2.1 mm (Phenomenex) and mobile phases: A-5 mM aqueous solution of ammonium
acetate pH 5.8, B-acetonitrile. The mobile phase flow was 0.4 mL min−1 and the oven temperature
was 30 ◦C. The following elution program was used: 0–2 min—10% isocratic B, 2–9 min from 10% to
70% B, 9–10 min—isocratic 70% B, 10–10.5 min—from 70% to 5% B, 10.5–14 min—isocratic 5% B. Mass
spectrometer parameters were as follows: nebulizing gas flow 3 L min−1, drying gas flow 8 L min−1,
temperature 250 ◦C desolvation line, 400 ◦C heating block temperature. The analyses were performed
in multiple reaction monitoring (MRM) mode.
2.9. Statistical Analyses
All of the data were expressed as the mean value and standard deviation of three biological
replicates. Data were analyzed using Microsoft Office Excel 2010 and Statistica® 13.3 PL (TIBCO
Software Inc., Palo Alto, CA, USA). In order to determine whether the pharmaceuticals or
bioaugmentation influenced the activity or metabolic properties of microorganisms in the AS, the
results were evaluated using ANOVA test. The statistical significance (p < 0.05) of any differences
were analyzed using one-way ANOVA for considering the effect of drugs or bioaugmentation on the
functional diversity indices and the usage of carbon substrates and evaluated by a post-hoc test of the
means using the lowest significant differences (LSD) test for normally distributed data or multiple
comparisons test (MCT) for results, which did not present normal distribution. For the cluster and
Spearman’s rank correlation analysis, data were first subjected to min–max normalization according to
the equation:
ND =
RDi −RDmax
RDmax −RDmin (3)
where, ND—normalized data (all of the variables were scaled to the range between 0 and 1); RDi—the
initial raw data; RDmin—the minimal value of each parameter in a data set; and RDmax—the maximal
value of each parameter in a data set. All of the factors that might have an influence on the changes
observed between non- and bioaugmented assays were evaluated by PCA analysis based on the
correlation matrix.
3. Results
3.1. The Impact of Pharmaceuticals and Bioaugmentation on the AS Quality
The results of the TPF concentration measurement indicated that the bioaugmented AS1 assay
was characterized by a higher overall metabolic activity compared to the non-bioaugmented assay AS2
(Figure 2). In turn, the bioaugmented biotic control AS4 was characterized by the lowest metabolic
activity within the tested systems. Considering the weak metabolic activity observed in the AS4,
the increase of this parameter for the AS1 resulted probably from the drugs degradation. It was
indicated that the high activity of the bacterial consortium in the control AS3 assay was inhibited by the
autochthonous microorganisms which was reflected in the lowest microbial activity in the assay AS4.
Moreover, the relatively high bacterial activity observed in the control AS3 was probably connected
with the high accessibility of nutrients released from the AS flocs.
In the AS1, THB (CFU mL−1) during the entire experiment was rather constant. Small differences
were also observed for the assay AS2. On the other hand, the greatest differentiation was revealed
for the AS3 and AS4 treatments, which were simultaneously characterized by the highest THB. It is
noteworthy that in the AS5 assay, to which neither consortia nor pharmaceuticals were added, there
was no sharp decrease in the number of microorganisms.
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COD (mg L−1 O2) measurements allowed to estimate system’s organic load. The lowest values
were calculated for the AS1 and AS4 assays, which indicated that the constructed bacterial consortium
was characterized by high efficiency in organic substances removal (Figure 3). For the AS1, the most
severe decline in the COD values was observed after 7 days of treatment (t7) and at the end of the
experiment (t30). For the assay AS2 containing the AS and pharmaceuticals, the COD values were
rather constant, with a slight drop on day 21 of the experiment (t21). However, for the AS2 the level of
the observed loading was significantly lower (maximum value reached 1672 mg L−1 O2) than those
observed for the AS5, where the COD values ranged from 4004 at t0 to 6160 mg L−1 O2 at t30, without
significant reduction at any sampling time.
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Figure 2. Bacteria consortium evolution weekly assessed by dehydrogenases activity (TPF,
µg g−1 h−1)—bars, and THB enumeration (log CFU mL−1)—points, on the experimental conditions
(assays AS1–AS5), during the experimental period (30 days). The data are presented as the mean values
of three biological replicates ± standard deviation. Columns marked with red asterisks are significantly
different (p < 0.05, multiple comparisons (MCT) test) considering different experi ental conditions at
the same sa pling time, and marked with black asterisks—within each assay considering the sampling
day. TPF—triphenyltetrazolium chloride, THB—Total Heterotrophic Bacteria.
In order to evaluate indirectly the biomass in each experimental condition, the concentration
of proteins relea d from the flocs was measur d (Figure 4). The obtained results sho ed that the
highest overall concentration of proteins was meas red in the biotic non-bioaugmented control AS5.
Considering e periodic feeding of the AS with fresh SW wi hout the ddition of bact ial consortium
and/or NSAIDs, good quality of the AS in this ass y was expected. Indeed, there were no severe
disturbances between the AS4 and AS5 assays that indicated no negative influenc of inoculat d
bacterial consortium on the AS condition. The general trends in protein concentrations were similar
for all tested systems. Similarly, the successive bioaugmentation was not significantly reflected in the
overall protein concentrations, because most of the differences were not statistically significant.
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The data are pr sented as the me n values of three biological replicates± sta dard deviation. The values
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post hoc lowest significant differences (LSD) test) considering different experimental conditions at the
same sampling time. The values of protein concentration with different upper-case letters (A, B, C, D, E)
are significantly different (p < 0.05, post hoc LSD test) within each assay considering the sampling day.
3.2. Microbial Activity in the Activated Sludge
To compare the metabolic activity and functional capacity of microorganisms in the tested systems,
the EcoPlateTM indices were estimated. It was indicated that the bioaugmentation of the AS caused a
slight increase in the microbial diversity at t0 what was observed as a significant difference in H’Eco
values between AS1/t0 and AS2/t0 (Table 3). The highest value of this parameter was calculated for AS5
at t30. Although the average and maximum microbial activity were the lowest in the non-bioaugmented
and not fed AS5 ass y, the microbial communities achieved half of their overall maximal activity in
the shortest time (Avt50) (Table 4). The presence of the pharmaceuticals in the assay AS2 significantly
influenced the microorganisms abundance, which was reflected in the higher G coefficient value
compared to its value calculated for the control AS5 assay. Neither the bioaugmentation nor the
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NSAIDs and APAP influenced the S index. Microorganisms in all assays were able to utilize 83%–89%
of the carbon sources available on the EcoPlate, which was correlated with the S values in the range
from 26 to 28.
To determine whether the presence of the NSAIDs or APAP and bioaugmentation affected the
utilization patterns in the experimental conditions, all EcoPlate substrates were grouped by their
chemical guild. It was found that the intensity of carbohydrates usage increased in the AS1 and
AS4 by 22% and 12% during the experimental period (30 days), respectively. Additionally, in the
assay AS1 fed with the pharmaceuticals a significant increase in carboxylic acids usage was also
recorded (Figures 5 and 6). The shifts in amino acids and amines utilization, reflecting the changes
in nitrogen sources usage, clearly indicated that inoculation of bacterial consortium into the AS1
and AS4 caused a significant decrease in the utilization of nitrogen containing substrates from 30%
to 20% and 22% during 30 days of wastewater treatment, respectively. In turn, the presence of the
NSAIDs and APAP in the assay AS2 caused a significant increase in phenolic acids utilization from
0.92% at t0 to 6.15% at t30. For microorganisms from the AS1 assay, the most significant difference
in the utilization pattern was in putrescine, pyruvic acid methyl ester, glycogen, and L-arginine
consumption, which were more intensively metabolized at t0 than at t30. Contrary, under the same
conditions they used less D-cellobiose, D-mannitol, and D-lactose. In comparison, the microorganisms
in the non-bioaugmented AS2 intensively metabolized at t0 carbon sources including e.g., glycogen,
D-mannitol, Tween 40, N-acetyl-D-glucosamine, or D-galactouronic acid. However, during the
following days of the experiment, the ability of microorganisms to utilize pyruvic acid methyl ester,
D-asparagine, L-serine, putrescine, and D-malic acid increased.Water 2020, 12, x FOR PEER REVIEW 12 of 25 
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Table 4. The kinetic parameters for the AS in different experimental conditions.
Parameter AS1/t0 AS2/t0 AS1/t30 AS2/t30 AS4/t30 AS5/t30
Kinetic Parameters
Amax 1.29 ± 0.04 ac 1.04 ± 0.13 b 1.32 ± 0.09 a 1.19 ± 0.05 ab 1.25 ± 0.10 ac 1.10 ± 0.06 bc
b 50.07 ± 5.63 a 129.88 ± 19.04 b 221.59 ± 34.59 cd 180.78 ± 19.50 bc 227.67 ± 30.22 d 674.21 ± 60.82 e
k 0.069 ± 0.004 a 0.082 ± 0.006 b 0.098 ± 0.003 c 0.100 ± 0.004 c 0.090 ± 0.002 d 0.148 ± 0.005 e
Avt50 57.15 ± 2.91 ac 58.054 ± 1.70 ad 54.78 ± 1.18 bc 52.65 ± 1.17 b 60.46 ± 1.46 d 44.62 ± 1.19 e
Amax—maximum microbial activity; b—the relative microbial activity increase in an arbitrary constant; k—the
specific rate of activity increase; Avt50—time at which the total microbial activity increased at the fastest rate. In each
row the means with different letters (a, b, c, d, e) are significantly different (p < 0.05, LSD test) considering different
experimental conditions and/or sampling day.Water 2020, 12, x FOR PEER REVIEW 13 of 25 
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Figure 6. Cluster analysis based on the Spearman’s rank correlation coefficients estimated for the
Biolog® EcoPlatesTM carbon sources utilization patterns for the different experimental conditions
(assays AS1, AS2, AS4, and AS5) during the experimental period (30 days). All data were normalized
and presented as a color scale ranging from green (MIN, means 0) to red (MAX, means 1).
3.3. Removal of Pharmaceuticals
As the obtained results showed, the degraded doses of APAP, IBU, and NPX were quite similar in
the bioaugmented AS1 and the non-bioaugmented AS2 assays (Table 5).
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Table 5. Degraded doses of analyzed pharmaceuticals in the AS1, AS2, and AS3 assays during 30 days
of treatment.
Pharmaceutical Time of Analysis Assay Degraded Dose (mg L−1)
APAP
t7
AS1 1.0
AS2 1.0
AS3 1.0
t14
AS1 1.0
AS2 1.0
AS3 1.0
t21
AS1 1.0
AS2 1.0
AS3 1.0
t30
AS1 1.0
AS2 1.0
AS3 1.0
IBU
t7
AS1 1.0
AS2 1.0
AS3 1.0
t14
AS1 1.0
AS2 1.0
AS3 1.0
t21
AS1 1.0
AS2 1.0
AS3 1.0
t30
AS1 1.0
AS2 1.0
AS3 0.94 ± 0.02
NPX
t7
AS1 0.5
AS2 0.5
AS3 0.5
t14
AS1 0.5
AS2 0.5
AS3 0.5
t21
AS1 0.5
AS2 0.5
AS3 0.5
t30
AS1 0.34 ± 0.00
AS2 0.32 ± 0.05
AS3 0.44 ± 0.01
DCF
t7
AS1 0.14 ± 0.08
AS2 0.12 ± 0.04
AS3 0.33 ± 0.04
t14
AS1 0.5 ± 0.00
AS2 0.34 ± 0.04
AS3 0.39 ± 0.02
t21
AS1 0.46 ± 0.01
AS2 0.31 ± 0.02
AS3 0.5
t30
AS1 0.49 ± 0.00
AS2 0.43 ± 0.05
AS3 0.48 ± 0.01
The data are presented as the mean values of three biological replicates ± standard deviation. The last period is
longer than the previous due to the measurements in the last day of the experiment (30 day).
Water 2020, 12, 1133 13 of 22
Over the experiment, the AS microorganisms in the AS1, AS2, and AS3 assays completely
utilized four doses of APAP and IBU. Degradation of NPX proceeded similarly in the AS1 and AS2
treatment with NPX residue at 0.16 ± 0.00−0.18 ± 0.05 mg L−1. More visible changes were observed
in DCF degradation, which was the most ineffective in the AS2 assays with the autochthonous
microorganisms. The residue of DCF in the AS2 at t7 was 0.38 ± 0.04 mg L−1, at t14—0.16 ± 0.04 mg L−1,
at t21—0.19 ± 0.02 mg L−1 and at t30—0.07 ± 0.05 mg L−1. The presence of the bacterial consortium in
the AS1 significantly enhanced DCF degradation compared to its removal by microorganisms in the
AS2, with DCF residue at t7—0.36 ± 0.08 mg L−1, at t14—0.00 ± 0.00 mg L−1, at t21—0.04 ± 0.01 mg L−1,
and at t30—0.01 ± 0.00 mg L−1. Simultaneously, the incomplete degradation of pharmaceuticals in the
AS3 assay with the sterilized AS and bacterial consortium indicated that the degradation of drugs in
the AS1 treatment was partly enhanced by the indigenous microorganisms. The final concentration
of IBU in the AS3 was 0.05 ± 0.02 mg L−1, NPX—0.06 ± 0.01 mg L−1, and DCF—0.02 ± 0.01 mg L−1,
whereas, APAP was not detected.
3.4. Secondary Metabolites Formation
In order to identify the most important secondary metabolites formed during the degradation of
the analyzed drugs, the AS from the assay AS1 was subjected to analysis using the UHPLC MS/MS.
The transition of m/z of the precursors to the m/z of the products is given in Table S1. By-products
identified after every 7 days of treatment are summarized in Table 6. Among the identified metabolites,
2-OH-IBU and 4-OH-DCF were characterized by the highest concentration.
Table 6. Secondary metabolites identified in the AS1 assay during 30 days of treatment.
Pharmaceutical Metabolite Time of Analysis RT UHPLC MS/MS (ng mL−1)
APAP
4-aminophenol t7 1.93 <40.0
t14 <40.0
t21 <40.0
t30 <40.0
Hydroquinone t7 nd nd
t14 nd
t21 nd
t30 nd
NPX O-desmethyl-NPX
t7
4.89
<20.0
t14 <20.0
t21 <20.0
t30 <20.0
IBU
1-OH-IBU t7 5.25 <5.0
t14 <5.0
t21 <5.0
t30 <5.0
2-OH-IBU t7 4.81 <5.0
t14 <5.0
t21 8.6 ± 0.1
t30 <5.0
DCF
DCF lactam t7 8.98 <20.0
t14 <20.0
t21 <20.0
t30 <20.0
4-OH-DCF t7 6.11 48.9 ± 0.7
t14 72.1 ± 2.2
t21 45.9 ± 3.4
t30 <20.0
The data are presented as the mean values of three biological replicates ± standard deviation. The last period is
longer than the previous due to the measurements in the last day of the experiment (30 day). RT—retention time
(min); nd—not detected.
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3.5. New Diclofenac-Degrading Strains
To impose a strong selection pressure, the higher concentrations of DCF than those detected in the
WWTPs effluents were used to isolate two new DCF-degrading bacterial strains. The phylogenetic
analysis of the isolates was performed based on the partial sequences of 16S rRNA, and two
housekeeping genes, pyrG and rpoB according to literature data [35]. Newly isolated strains were
assigned as Serratia proteamaculans AS4 and Rahnella bruchi AS7 (Figure 7). It is worth emphasizing that
this is the first report about Serratia and Rahnella able to degrade DCF. Both strains are rod-shaped
Gram-negative bacteria with creamy, smooth, and glossy colonies. The abilities of both strains to
degrade DCF were studied under the co-metabolic conditions with glucose, because none of them were
capable of utilizing DCF as a sole carbon and energy source. It was found that under such conditions
S. proteamaculans AS4 and R. bruchi AS7 were able to degrade DCF at the concentrations of 0.479 and
0.540 mg L−1 within 14 days, respectively (Figure 8).Water 2020, 12, x FOR PEER REVIEW 17 of 25 
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Figure 7. Phylogenetic tree of the newly isolated strains Serratia proteamaculans AS4 and Rahnella
bruchi AS7 based on the partial sequences of 16S rDNA, and two housekeeping genes: CTP synthase
(pyrG) and subunit beta of RNA polymerase (rpoB). Branching percentage values were determined
with the use of 1000 bootstraps phylogeny test. The accession number for genomes are shown in
brackets. The tree was constructed using the maximum likelihood method. The scale bar represents 1%
nucleotide sequence divergence.
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Figure 8. Changes in the optical density (OD600) and degradation of DCF by S. proteamaculans AS4 and
R. bruchi AS7 under co-metabolic conditions with glucose (1 g L−1). The data are presented as the mean
values of three biological replicates ± standard deviation.
4. Discussion
4.1. The Impact of Bioaugmentation and Pharmaceuticals on the AS Quality and Metabolic Diversity
Due to the incomplete removal and poor biodegradability, the NSAIDs and other analgesics are
among the most frequently detected organic contaminants in different natural matrices. Moreover, the
lack of sustainable approaches for the removal of the NSAIDs contributes to their continuous release
to the environment in the parent forms or as active or more stable metabolites [37]. This can lead
to their accumulation in trophic chains and cause long-term adverse effects in living organisms [38].
For pharmaceuticals removal, the AS technology frequently followed by additional physicochemical
methods is widely used in various European Union countries [39]. It is worth emphasizing that
biodegradation is the dominant mechanism for the removal of acidic drugs, i.e., IBU, NPX, and DCF,
while sorption and volatilization appear to be of secondary importance [40,41]. This is especially
important for DCF, the most toxic NSAID among those chosen for analysis, due to its weak adsorption
on suspended solids, which results from the occurrence of DCF molecule in the form of an ion at
neutral pH [42]. However, it is worth noting that in the literature, some contradictory results about the
sorption of the NSAIDs to the AS flocs were published—some authors reported that sorption is relevant
for hydrophobic compounds e.g., the poly-cyclic NSAIDs [41]. Despite that, in most published papers
related to sorption of the NSAIDs, the authors highlighted that these mechanisms are negligible [42].
Although bioaugmentation has proven to be a valuable strategy to improve the operational
parameters of the biological wastewater treatment systems and enhance the removal of various
pollutants, there is scarce information about its application for the treatment of wastewater containing
the prevalent pharmaceuticals [43]. In this study, we focused mainly on the metabolic response and
biochemical diversity alterations in the AS during feeding with low concentrations of the drugs.
As Almeida et al. [44] reported, biodegradation is rarely studied in terms of the mixture of NSAIDs
and analgesics, where synergistic effects of the presence of one drug on another are widely observed. It
is well known that a combination of different compounds can affect biodegradation due to its inhibition
or by competition and toxicity [44,45].
In the present study, the multidirectional effects of the mixture of four popular analgesics present
in wastewater at low concentrations as well as the successive bioaugmentation of the AS with
pharmaceuticals-degrading strains on the AS quality were studied. The bioaugmentation of the AS
with the designed microbial consortium was intended to enhance the removal efficiency of selected
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analgesics. It is generally considered as a safe method of bioremediation if it does not disturb the
balance of the ecosystem into which allochthonous microorganisms are introduced. The indicator of
this equilibrium may be the metabolic activity and diversity of the entire microbiome. Simultaneously,
the metabolic activity of the AS microbial communities is the crucial indicator of the effectiveness of
biological wastewater treatment [46]. So far, the functional capacity of the AS microorganisms that have
been exposed to the NSAIDs and APAP is not well documented or discussed in the literature. Herein,
the inoculation of the AS1 assay with the bacterial consortium caused a slight increase in the metabolic
activity and metabolic richness compared to the non-bioaugmented assay AS2. It might indicate that
the composition and number of introduced microorganisms were correctly estimated—on the one hand,
the selected consortium did not dominate in the AS, on the other hand its addition positively correlated
with the increase in the functional diversity in this ecosystem. Therefore, it could be suggested that there
was no competition for the carbon sources and incompatibility between the inoculated consortium and
autochthonous microorganisms. If the number of introduced microorganisms is too high, a decrease
in the H’ECO value can be expected. Such a relationship was reported by Hailei et al. [47] through
the metagenomic sequencing of the bioaugmented AS treated with coking wastewater. Similarly, the
inoculation of the AS with Phanerochaete chrysosporium increased bacterial and eukaryotic richness
but reduced their diversity. The increase in the metabolic richness index in the bioaugmented AS in
the initial phase of the experiment was also observed in this study and it was connected with more
intense metabolism of such substrates as putrescine, pyruvic acid methyl ester, L-asparagine, and
L-arginine. This could suggest that the introduction of bacterial consortium permitted the utilization
of a wider group of substrates by microbial communities compared to the non-bioaugmented AS.
The utilization patterns of seven selected biochemical guilds were found to vary in the particular
AS assays during 30 days of treatment. It can be suggested that no further changes in the S values
observed for the AS assays after that period could be a result of metabolic specialization of the
AS microorganisms caused by the presence of allochthonous bacterial strains and/or analgesics as
additional carbon sources. The autochthonous AS microorganisms increased utilization of phenolic
compounds and those containing nitrogen, while carboxylic acids and carbohydrates were metabolized
more intensively in the bioaugmented AS. The intensification of metabolism of phenolic compounds
and those containing nitrogen by the AS microorganisms as the microbial response to the presence of
harmful leachate from the Kalina pond (S´wie˛tochłowice, Poland) in wastewater was also observed
by Michalska et al. [16]. The authors assumed that the presence of the leachate in wastewater caused
the metabolic specialization of the AS microorganisms with the simultaneous loss of the functionally
significant microorganisms. In this study, such drastic shifts were not observed—the activity and
functional diversity of the AS microorganisms did not decrease after exposure to low concentrations
of analgesics and/or the inoculation of the bacterial consortium. Moreover, the biomass and THB
remained also rather constant. This might indicate that applied treatments did not disturb the balance
of the AS microbial communities under fluctuating conditions in this ecosystem. Additionally, the
overall metabolic activity expressed as the activity of dehydrogenases in the bioaugmented AS exposed
to the analgesics (assay AS1) was higher compared to the non-bioaugmented AS (assay AS2 on days 21
and 30 of the experiment). It could suggest that the bacterial consortium stimulated the metabolic
activity of the AS microorganisms in the long-term presence of the NSAIDs and APAP as the additional
carbon sources. In comparison, the absence of the analgesics in the bioaugmented AS (assay AS4)
caused the decrease in the activity of autochthonous microbial communities on days 21 and 30 of
the experiment, what indicated that the additional carbon sources affected the metabolism of the AS
microorganisms. Simultaneously, a rather constant total count of heterotrophic bacteria in the AS1 and
AS2 assays suggested that the exposure of microorganisms to the NSAIDs and APAP did not eliminate
drastically microbial species from the AS. Similarly, Hu et al. [48] observed that the microorganisms
originated from the AS were well acclimated and degraded a low initial concentration of plasticizer
di-n-butyl phthalate (10 mg L−1), while at a higher concentration (100 mg L−1) they poorly removed it.
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The solution was the bioaugmentation of the AS with Micrococcus sp. which enhanced the removal
efficiency of higher concentration of the target compound.
4.2. Pharmaceuticals Removal and Secondary Metabolites Formation
In this study, we focused on the visualization and proving that low concentrations of the analgesics,
which are detected in the influents are efficiently removed from the sewage, since the large body of the
literature is concerned about the concentrations far exceeding those detected in the environment [10].
The abiotic control SWc established within this study confirmed that the removal of the analyzed drugs
resulted from the biological activity of the AS microflora. Considering the NSAIDs adsorption, the
sorbed pharmaceuticals onto the bacterial surface are frequently released into the medium during the
long-period analysis and we did not observe such a phenomenon. The biodegradation hypothesis is
also further supported by secondary metabolites formation detected by UHPLC MS/MS. A similar
conclusion was made by Almeida et al. [44] who investigated the degradation of the NSAIDs mixture by
the AS from three different WWTPs. Generally, the biodegradation kinetics in the bioaugmented assay
AS1 and the non-bioaugmented AS2 followed a similar trend, especially for APAP, which was utilized
with equal efficiency in both systems. Efficient biodegradation of APAP, the monocyclic analgesic with
relatively simple chemical structure was expected in both the bioaugmented and non-bioaugmented
systems. Similar observations were made by De Gusseme et al. [49] who demonstrated that after 16 days
of operation at a hydraulic retention time of 5 days in a membrane bioreactor, upward of 99.9% removal
of the administered dose of APAP (100 µg L−1) was obtained. The established microbial consortium
was also able to degrade APAP at an environmentally relevant concentration of 8.3 µg L−1. Moreover,
under the batch incubation conditions with heat-killed microorganisms the biological removal of APAP
has been confirmed since its sorption to the biomass was negligible. In comparison, IBU with a high
branch structure and the presence of substitutions at the para position of the aromatic ring is found
as more resistant to biodegradation than APAP [50,51]. In this study, any significant changes in the
removal of tested pharmaceuticals between microorganisms in the AS1 and AS2 assays were observed.
Physicochemical properties of IBU molecule may determine its relatively high mobility in waters
but, in comparison with other pharmaceuticals, its persistence may be lower [52]. Considering our
results, this hypothesis is more probable. For IBU, the AS autochthonous microflora was equally able
to metabolize IBU at the chosen concentration. Similar results were obtained by Almeida et al. [44]
who investigated the degradation of IBU at the concentration of 0.5–1.0 mg L−1 by the AS derived
from three different municipal WWTPs. For DCF, to date, only a few reports about degradation
have been published, e.g., by attached growth biomass from a carrier-filled compartment of a hybrid
bioreactor at the WWTP, microbial removal investigated in a MBR, or DCF removal by microorganisms
from agricultural soils [53–55], however, microorganisms responsible for its biodegradation have
not been identified. As a consequence, limited information regarding microorganisms responsible
for DCF utilization and microbial processes underlying the degradation of its residues are available.
The sensitivity of microorganisms to this compound could be partly responsible for the harmful effects
of DCF and/or DCF-containing mixtures on the microbial biodiversity in the AS. Jewell et al. [56]
revealed 88% removal of the initial concentration of DCF (1.6 µg L−1) in the influent of the full-scale
WWTP during 10-day monitoring experiment and confirmed the formation of several by-products. In
this study, significant differences in DCF removal were found between the bioaugmented assay AS1 and
non-bioaugmented AS2. It was probably caused by the inoculation of the AS with P. moorei KB4 strain,
which can metabolize relatively high concentrations of DCF. For NPX, the second analyzed polycyclic
NSAIDs, the dynamics rates were quite similar for the AS1 and AS2 assays. Considering its high
resistance to the biological treatment, extremely limited knowledge about degradation pathways and
microorganisms capable of degrading this NSAID, the bioaugmentation strategy may be a promising
tool for the successful removal of NPX in wastewater [57]. Despite the relatively large release of the
analyzed pharmaceuticals into the environment, the knowledge about the metabolic pathways of their
degradation remains still not fully understood. The partial metabolic pathways and key metabolites
Water 2020, 12, 1133 18 of 22
formed during the degradation of tested pharmaceuticals by bacterial strains used in the consortium
were established in the previous studies [31,51,58]. For APAP, the two most frequently detected
microbial metabolites include hydroquinone and 4-aminophenol [21,31,59,60]. In this study, in the
assay AS1 both metabolites were identified and efficiently removed by the AS communities. For IBU,
the hydroxy- and carboxyibuprofen derivatives are described as the most commonly detected in the
WWTPs effluents [61]. The formation of both 1-OH-IBU and 2-OH-IBU metabolites were observed in
the AS1 assay, although, the analysis performed with the use of UHPLC MS/MS revealed that both
metabolites were efficiently degraded. Over 30 days of treatment, the accumulation of 2-OH-IBU in
the AS1 was observed at t21, however, its presence was not further revealed (t30). The accumulation
of O-desmethylnaproxen, a key by-product of NPX degradation, identified e.g., for B. thuringiensis
B1(2015b) [58], was excluded by the UHPLC MS/MS analysis. For DCF, 4-OH-DCF and lactam DCF
are known as one of the most important initially formed secondary metabolites during microbial
degradation [56]. The constant presence of 4-OH-DCF was confirmed in the AS1 assay using the
UHPLC MS/MS with the highest value at t21. Noteworthy, after every 7 days of the AS1 assay operation,
none of the tested drugs were found. Moreover, further analysis confirmed that key by-products
were metabolized by the same microorganisms, which clearly indicated that examined drugs at low
concentrations as well as their key metabolites were not accumulated. Considering that most of the
organic pollutants and their by-products are characterized by high toxicity and chemical stability,
from the environmental point of view biodegradation of the mature compound and its metabolites is
extremely beneficial.
4.3. Isolation of New DCF-Degrading Strains
The novelty of this work relates also to the isolation of two new bacterial strains
Serratia proteamaculans AS4 and Rahnella bruchi AS7 able to DCF degrade. Although the 16S rRNA
sequence is widely used to establish the taxonomy of the newly isolated strains due to its high
conservation, failing to provide proper phylogenetic resolution to assigned analyzed strains to the level
of species [62,63]. Thus, MLST analysis performed in this study based on the two additional genes
provided better discrimination of the phylogenetic analysis. To date, only a few DCF-metabolizing
bacterial strains have been isolated, e.g., Enterobacter hormachei D15 [42], Raoultella sp. DD4 [64],
Brevibacterium sp. D4 [65], Raoultella sp. KDF8 [66], Labrys portucalensis F11 [67], and Klebsiella sp.
KSC [68]. The ability of new isolates to degrade DCF were studied under the co-metabolic conditions
with glucose, because none of them were able to metabolize DCF as a sole carbon and energy source.
Supplementation with the additional carbon source frequently ensures the increase in the bacterial
biomass and, simultaneously, better degradation of the drug [29]. Similarly, glucose as an external carbon
source applied by Aissaoui et al. [42] under co-metabolic degradation of DCF by Enterobacter hormaechei
D15 strain significantly intensified biodegradation efficiency. In turn, Moreira et al. [67] intensified
biodegradation of DCF by Labrys portucalensis F11 strain by periodic feeding with sodium acetate,
which allowed to obtain higher bacterial density. In this study, S. proteamaculans AS4 and R. bruchi AS7
were able to degrade almost 0.5 mg L−1 of DCF which definitely exceeds the detected environmental
concentrations of this drug.
5. Conclusions
The AS technology is an effective method for treating the wastewater containing selected mono-
and polycyclic NSAIDs and/or analgesics. The bioaugmentation of the AS with bacterial strains with
naturally increased degradative capabilities seems to be a promising solution for the removal of poorly
biodegradable pharmaceuticals e.g., DCF and NPX. In this study, the addition of the designed microbial
consortium consisting of three pharmaceuticals-degrading strains did not cause any severe changes in
the biomass and metabolic activity of the AS microorganisms. Moreover, in the metabolic properties of
the autochthonous microflora any significant changes were not found. Nevertheless, the introduced
strains intensified the metabolism of different groups of substrates compared to the non-bioaugmented
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AS. Throughout the experiment, we identified a few key secondary metabolites including hydroxylated
derivatives of IBU and DCF. Additionally, two new DCF-degrading isolates were obtained from the
non-bioaugmented AS, namely Serratia proteamaculans AS4 and Rahnella bruchi AS7.
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